^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    melphalan

    i
    Other names: L-PAM, L-sarcolysin, phenylalanine mustard
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    3d
    A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (clinicaltrials.gov)
    P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)
    |
    TP53 mutation
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan
    5d
    A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC) (clinicaltrials.gov)
    P2, N=242, Active, not recruiting, University of Birmingham | Trial primary completion date: Nov 2024 --> Oct 2025
    Trial primary completion date
    |
    cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • mesna
    10d
    Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1, N=33, Recruiting, City of Hope Medical Center | Trial completion date: Jun 2027 --> Mar 2030 | Trial primary completion date: Jun 2027 --> Mar 2030
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    melphalan • fludarabine IV • thiotepa • Orca-T
    10d
    CALGB-100104: Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant (clinicaltrials.gov)
    P3, N=460, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Mar 2027
    Trial completion date
    |
    lenalidomide • melphalan
    10d
    Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=306, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    lenalidomide • thalidomide • melphalan
    12d
    Clinical Study on the Preservation of Ovarian Function Following Hematopoietic Stem Cell Transplantation in Patients With Malignant Hematologic Diseases Using Goserelin (clinicaltrials.gov)
    P=N/A, N=64, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    melphalan • goserelin acetate
    12d
    Clinical Study on the Preservation of Ovarian Function Following Autologous Hematopoietic Stem Cell Transplantation Using Goserelin (clinicaltrials.gov)
    P=N/A, N=64, Not yet recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    New trial
    |
    melphalan • goserelin acetate
    16d
    A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg (clinicaltrials.gov)
    P2, N=30, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2026 --> Apr 2027 | Trial primary completion date: Apr 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • melphalan • dactinomycin
    18d
    Study of Thiotepa Combination With Melphalan (TM Protocol) Conditioning for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma：A Prospective Randomized Controlled Clinical Trial (clinicaltrials.gov)
    P=N/A, N=204, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University
    New trial
    |
    CD34 (CD34 molecule)
    |
    melphalan • thiotepa
    19d
    CAR-T+ASCT: CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors. (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Zhejiang Cancer Hospital
    New P2 trial
    |
    TP53 (Tumor protein P53) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    TP53 mutation
    |
    cytarabine • Yescarta (axicabtagene ciloleucel) • carmustine • melphalan
    23d
    Therapy for Children With Advanced Stage Neuroblastoma (clinicaltrials.gov)
    P2, N=153, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed
    Trial completion
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • daretabart (hu1418K322A)
    23d
    UHKT-PTC-TMI-1: Proton-Based Total Marrow Irradiation for Allogeneic Transplantation in High-Risk AML/MDS (clinicaltrials.gov)
    P1/2, N=16, Recruiting, Institute of Hematology and Blood Transfusion, Czech Republic
    New P1/2 trial
    |
    cyclophosphamide • melphalan • fludarabine IV